Hillary Clinton's War on Pharma II; A call for common sense reporting on Alzheimer's R&D
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
Hillary Clinton wanted that war with pharma, badly
For all the backlash around Martin Shkreli’s brief, disastrous turn as CEO of Turing, the Tweet from Hillary Clinton condemning his price gouging stands out for the widespread damage it did to biotech stocks. There are lots of reasons why the biotech stock indexes have tanked over the past year. And it’s easy to see why that may have been overdue. But having a presidential candidate use Shkreli to declare a “war on pharma” sets the stage for the battle to continue in DC after the votes are counted. Trying to score cheap points with voters in a primary is a bad way to establish policy. Yet that is what we are looking at if Clinton is elected. The US — and the badly fractured health system that needs reforming — deserve better. And biotech has enough problems right now without getting caught up in the war. Let’s urge Clinton to take a more responsible stand if she wins the big election Tuesday.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.